On June 30, BeOne Medicines (06160.HK) fell 3.21% in regular trading, trading at HKD 168.6/share, with turnover of HKD 311 million.

On the news front, the broader biotechnology sector experienced a collective pullback, creating broad-based selling pressure. Within the sector, AKESO fell 4.8%, Remegen fell 5.65%, TransThera-B fell 6.92%, and 3SBIO fell 2.78%, indicating widespread risk-off sentiment across the biotech space.

The decline also reflects continued digestion of the company's June 26 announcement that a domestic wholly-owned subsidiary was required to pay approximately RMB 446 million in back taxes and late payment surcharges following a notice from local tax authorities. The company stated the matter does not involve administrative penalties and is not a prior-period accounting error. The amount is roughly equivalent to one month of net profit based on Q1 earnings. The stock had fallen 4.37% on A-shares on June 27 and rebounded 3.01% on June 29 before retreating again, suggesting the market continues to weigh the tax impact alongside sector-wide adjustment pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)